BCRX logo

BCRX
Biocryst Pharmaceuticals Inc.

36,905
Mkt Cap
$2.39B
Volume
3,015.00
52W High
$11.31
52W Low
$6.00
PE Ratio
7.91
BCRX Fundamentals
Price
$9.52
Prev Close
$9.44
Open
$9.45
50D MA
$8.50
Beta
0.90
Avg. Volume
6.83M
EPS (Annual)
$1.21
P/B
-17.02
Rev/Employee
$2.01M
$1,907.31
Loading...
Loading...
News
all
press releases
Phocas Financial Corp. Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX
Phocas Financial Corp. acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
SG Americas Securities LLC Sells 102,210 Shares of BioCryst Pharmaceuticals, Inc. $BCRX
SG Americas Securities LLC lessened its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 44.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC...
MarketBeat·7d ago
News Placeholder
Aberdeen Group plc Buys Shares of 913,593 BioCryst Pharmaceuticals, Inc. $BCRX
Aberdeen Group plc acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange...
MarketBeat·8d ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6% - Here's What Happened
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6% - Should You Buy...
MarketBeat·11d ago
News Placeholder
Investors Purchase High Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Stock traders acquired 9,003 call options on the stock. This...
MarketBeat·15d ago
News Placeholder
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX
Assenagon Asset Management S.A. trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 88.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 359,580 shares of the biotechnology co...
MarketBeat·17d ago
News Placeholder
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co.
JPMorgan Chase & Co. lowered its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 28.5% during the 3rd quarter, according to its most recent 13F filing with the...
MarketBeat·18d ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - What's Next?
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - Should You Buy...
MarketBeat·24d ago
News Placeholder
Nasdaq, S&P 500 Futures Rise Ahead Of PMI Data, Iran Tensions Cap Risk Appetite: Why NVDA, GME, AAOI, BCRX Are Keeping Traders Engaged Today
Data from Stocktwits indicated that retail sentiment has remained bearish on SPY and QQQ for over a week.
Stocktwits·24d ago
News Placeholder
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen brokerages that are presently covering the stock, MarketBeat...
MarketBeat·24d ago
<
1
2
...
>

Latest BCRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.